MCID: HMT018
MIFTS: 54

Hematopoietic Stem Cell Transplantation

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Hematopoietic Stem Cell Transplantation

MalaCards integrated aliases for Hematopoietic Stem Cell Transplantation:

Name: Hematopoietic Stem Cell Transplantation 59 38

Characteristics:

Orphanet epidemiological data:

59
hematopoietic stem cell transplantation
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

ICD10 via Orphanet 34 Z94.8
Orphanet 59 ORPHA90053

Summaries for Hematopoietic Stem Cell Transplantation

MalaCards based summary : Hematopoietic Stem Cell Transplantation is related to post-transplant lymphoproliferative disease and aspergillosis. An important gene associated with Hematopoietic Stem Cell Transplantation is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include t cells, myeloid and bone, and related phenotypes are digestive/alimentary and liver/biliary system

Wikipedia : 75 Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem... more...

Related Diseases for Hematopoietic Stem Cell Transplantation

Diseases related to Hematopoietic Stem Cell Transplantation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1236)
# Related Disease Score Top Affiliating Genes
1 post-transplant lymphoproliferative disease 33.1 TNF IL6 IL10
2 aspergillosis 32.9 TNF IL10 IFNG CLEC7A
3 chronic graft versus host disease 32.3 TNF IL10 IFNG
4 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 32.1 IL2 IL10 IFNG
5 chronic active epstein-barr virus infection 31.9 IL2 IL10 IFNG CTLA4
6 candidiasis 31.5 IL10 IFNG CLEC7A
7 pneumonia 31.4 TNF IL6 IL10
8 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 IL10 IFNG CTLA4
9 hemophagocytic lymphohistiocytosis 31.2 TNF IL10 IFNG
10 acute graft versus host disease 31.2 TNF IL2 IL10 IFNG ARHGAP45
11 bronchiolitis 31.1 TNF IL6 IL10 IFNG
12 relapsing-remitting multiple sclerosis 31.1 TNF IL10 IFNG
13 bronchiolitis obliterans 31.1 TNF IL6 IL10 IFNG
14 sclerosing cholangitis 31.0 TNF HLA-C HLA-B
15 gastroenteritis 31.0 TNF IL6 IL10
16 bacterial infectious disease 30.9 TNF IL6 IL10 IFNG
17 leishmaniasis 30.8 TNF IL10 IFNG
18 poliomyelitis 30.8 TNF IL10 IFNG
19 cholangitis 30.7 TNF IL6 HLA-B
20 omenn syndrome 30.7 TNF IL10 IFNG
21 viral encephalitis 30.7 TNF IL6 IL10
22 rubella 30.7 TNF IL10 HLA-B HLA-A
23 toxoplasmosis 30.7 TNF IL6 IL10 IFNG
24 postherpetic neuralgia 30.6 HLA-B HLA-A
25 cytomegalovirus retinitis 30.6 TNF IFNG HLA-B HLA-A
26 myocarditis 30.6 TNF IL6 HLA-B
27 hepatitis a 30.6 TNF IL10 IFNG
28 rheumatic disease 30.5 TNF IL10 IFNG HLA-B
29 demyelinating disease 30.5 TNF IL10 IFNG
30 keratoconjunctivitis sicca 30.5 TNF IL6 IL10
31 pertussis 30.5 TNF IL6 IL10
32 endocarditis 30.4 TNF IL6 IL10
33 large granular lymphocyte leukemia 30.4 KIR2DL3 IFNG
34 lymphadenitis 30.4 TNF IL10 IFNG
35 cytomegalovirus infection 30.4 TNF IL6 HLA-E HLA-B HLA-A
36 pericarditis 30.3 TNF IL6 IFNG
37 bacterial meningitis 30.3 TNF IL6 IL10
38 exanthem 30.3 TNF IL6 IL2 CTLA4
39 trichosporonosis 30.3 TNF IFNG
40 otitis media 30.3 TNF IL6 IL10
41 orofacial granulomatosis 30.3 TNF IL10 IFNG
42 spondylitis 30.3 TNF IL6 HLA-C HLA-B
43 graft-versus-host disease 30.2 TNF IL6 IL2 IL10 IFNG HLA-C
44 nervous system disease 30.2 TNF IL6 IL10 IFNG
45 periodontitis 30.2 TNF IL6 IL10 IFNG
46 transverse myelitis 30.2 TNF IL6 IL10
47 tetanus 30.1 IL2 IL10 IFNG
48 meningitis 30.1 TNF IL6 IL10 IFNG
49 pyelonephritis 30.1 TNF IL6 IL10
50 mumps 30.1 TNF IL2 IFNG

Graphical network of the top 20 diseases related to Hematopoietic Stem Cell Transplantation:



Diseases related to Hematopoietic Stem Cell Transplantation

Symptoms & Phenotypes for Hematopoietic Stem Cell Transplantation

MGI Mouse Phenotypes related to Hematopoietic Stem Cell Transplantation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CLEC7A CTLA4 IFNG IL10 IL2 IL6
2 liver/biliary system MP:0005370 9.5 CTLA4 IFNG IL10 IL2 IL6 MTHFR
3 respiratory system MP:0005388 9.17 CLEC7A CTLA4 IFNG IL10 IL2 IL6

Drugs & Therapeutics for Hematopoietic Stem Cell Transplantation

Drugs for Hematopoietic Stem Cell Transplantation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 523)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Ferrous succinate Approved Phase 4 10030-90-7
4
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
5
Epirubicin Approved Phase 4 56420-45-2 41867
6
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
7
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
8
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
9
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
10
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
13
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
14
Cobalamin Experimental Phase 4 13408-78-1 6857388
15
Treosulfan Investigational Phase 4 299-75-2 9296
16
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
17 Vitamin B 12 Phase 4
18 Vitamin B12 Phase 4
19 Dexamethasone 21-phosphate Phase 4
20 Ionophores Phase 4
21 Plerixafor octahydrochloride Phase 4
22 Anti-HIV Agents Phase 4
23 Anti-Retroviral Agents Phase 4
24 Antiparasitic Agents Phase 4
25 Antiprotozoal Agents Phase 4
26 Adrenergic Agonists Phase 4
27 Adrenergic beta-2 Receptor Agonists Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Anti-Asthmatic Agents Phase 4
30 Bronchodilator Agents Phase 4
31 Parasympatholytics Phase 4
32 Tocolytic Agents Phase 4
33 Tiotropium Bromide Phase 4 136310-93-5
34 Albuterol Phase 4
35 Bromides Phase 4
36 Gemtuzumab Phase 4
37 MF59 oil emulsion Phase 4
38 Cyclosporins Phase 4
39 Protein Kinase Inhibitors Phase 4
40 Ganciclovir triphosphate Phase 4
41 Immunoconjugates Phase 4
42 Reverse Transcriptase Inhibitors Phase 4
43 Imatinib Mesylate Phase 4 220127-57-1 123596
44 14-alpha Demethylase Inhibitors Phase 4
45 Cytochrome P-450 CYP3A Inhibitors Phase 4
46 Cytochrome P-450 Enzyme Inhibitors Phase 4
47 Steroid Synthesis Inhibitors Phase 4
48
Hydroxyitraconazole Phase 4
49 Pharmaceutical Solutions Phase 4
50 Cytochrome P-450 CYP2C9 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 1278)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
2 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
3 A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
4 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
6 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
7 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
8 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
9 Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia Unknown status NCT02838992 Phase 4 Rabbit ATG, (Genzyme);Cy;CsA
10 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
11 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
12 A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. Completed NCT01610297 Phase 4 ICL670
13 A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present Completed NCT00654589 Phase 4 Deferasirox
14 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
15 Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation Completed NCT01112241 Phase 4 albuterol plus tiotropium
16 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
17 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
18 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
19 A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Completed NCT02560909 Phase 4
20 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
21 Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects Completed NCT02056210 Phase 4 Mozobil
22 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
23 Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study Recruiting NCT04009525 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Thymoglobulin;cyclosporine A;Mycophenolate mofetil;Tacrolimus;Methotrexate;Basiliximab;Ruxolitinib
24 Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major Recruiting NCT03171831 Phase 4 Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
25 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
26 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
27 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
28 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
29 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
30 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
31 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
32 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
33 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
34 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
35 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
36 A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
37 Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial Unknown status NCT02313792 Phase 3 Palifermin
38 Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study Unknown status NCT02059720 Phase 3
39 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
40 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
41 Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant Unknown status NCT02240992 Phase 2, Phase 3
42 Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases Unknown status NCT02327351 Phase 2, Phase 3
43 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
44 Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia Unknown status NCT02474290 Phase 2, Phase 3 Sorafenib
45 Hematopoietic Stem Cell Transplantation in Myeloma Unknown status NCT00415987 Phase 2, Phase 3
46 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
47 Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1) Unknown status NCT01246752 Phase 3 Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
48 A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation Unknown status NCT02487563 Phase 3 decitabine;rhTPO
49 Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis Unknown status NCT01238328 Phase 2, Phase 3 Conditioning regimen;Graft-versus-host disease (GVHD) prophylaxis
50 A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient Unknown status NCT01766375 Phase 3 Cyclosporin A,mycophenolate mofetil,Methotrexate

Search NIH Clinical Center for Hematopoietic Stem Cell Transplantation

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Genetic Tests for Hematopoietic Stem Cell Transplantation

Anatomical Context for Hematopoietic Stem Cell Transplantation

MalaCards organs/tissues related to Hematopoietic Stem Cell Transplantation:

41
T Cells, Myeloid, Bone, Bone Marrow, B Cells, Lung, Nk Cells

Publications for Hematopoietic Stem Cell Transplantation

Articles related to Hematopoietic Stem Cell Transplantation:

(show top 50) (show all 16248)
# Title Authors PMID Year
1
Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis. 38
30129389 2019
2
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. 38
30757960 2019
3
Diagnosis and treatment of juvenile myelomonocytic leukemia. 38
31389303 2019
4
Differences in pulmonary and extra-pulmonary characteristics in severely versus non-severely fatigued recipients of allogeneic hematopoietic stem cell transplantation: a cross-sectional, comparative study. 38
30261831 2019
5
Upfront autologous hematopoietic stem cell transplantation in patients with high-risk stage III to IV Hodgkin lymphoma: a multicenter retrospective cohort study. 38
31081725 2019
6
High expression of miR-338 is associated with poor prognosis in acute myeloid leukemia undergoing chemotherapy. 38
30997674 2019
7
Viral infections and immune reconstitution interaction after pediatric allogenic hematopoietic stem cell transplantation. 38
31380705 2019
8
Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia. 38
31201644 2019
9
Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia. 38
31132205 2019
10
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. 38
31312927 2019
11
Medication Errors in the Context of Hematopoietic Stem Cell Transplantation: A Systematic Review. 38
29863578 2019
12
Antibiotic-Induced Shifts in Fecal Microbiota Density and Composition during Hematopoietic Stem Cell Transplantation. 38
31262981 2019
13
Cellular therapy for acute myeloid Leukemia - Current status and future prospects. 38
31109711 2019
14
Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: Identification of responding patients. 38
31211880 2019
15
Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. 38
31201514 2019
16
Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation. 38
31257540 2019
17
[Management of myelodysplastic syndromes in 2019: An update]. 38
31054780 2019
18
Structural Differences in Meibum From Donors After Hematopoietic Stem Cell Transplantations. 38
31261179 2019
19
Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. 38
31177565 2019
20
Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. 38
31376591 2019
21
Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada. 38
31325731 2019
22
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Respond to author. 38
30868268 2019
23
Zinc deficits, mucositis, and mucosal macrophage perturbation: is there a relationship? 38
31335336 2019
24
The Power of Reiki: Feasibility and Efficacy of Reducing Pain in Children With Cancer Undergoing Hematopoietic Stem Cell Transplantation. 38
31046557 2019
25
Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies. 38
31243569 2019
26
Bronchoscopic features, associations, and outcomes of organizing pneumonia following allogeneic hematopoietic stem cell transplantation. 38
31273420 2019
27
[Research Progress on Role of Gene Mutations in Prognostic Evaluation of Patients with Myelodysplastic Syndrome after Stem-Cell Transplantation--Review]. 38
31418402 2019
28
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. 38
30880268 2019
29
The early diagnostic value of serum galactomannan antigen test combined with chest computed tomography for invasive pulmonary aspergillosis in pediatric patients after hematopoietic stem cell transplantation. 38
31211850 2019
30
Relationship between the blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplant recipients
. 38
31426903 2019
31
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. 38
31012967 2019
32
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo). 38
31400502 2019
33
Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). 38
31392462 2019
34
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. 38
30537550 2019
35
Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia-A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP. 38
31095771 2019
36
Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. 38
30993415 2019
37
Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD. 38
31138510 2019
38
HSV-associated erythema multiforme in a patient after hematopoietic stem cell transplantation. 38
31414706 2019
39
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. 38
30951841 2019
40
Pediatric unmanipulated haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide and reduced intensity, TBI-free conditioning regimens in salvage transplantations. 38
31430069 2019
41
A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD. 38
31434801 2019
42
Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. 38
30518981 2019
43
A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. 38
30546068 2019
44
A Practical Guide to Gynecologic and Reproductive Health in Women Undergoing Hematopoietic Stem Cell Transplant. 38
31394266 2019
45
Allogeneic bone marrow versus peripheral blood stem cell transplantation for hematological malignancies in children: a systematic review and meta-analysis. 38
31394270 2019
46
Salvianolic acid B ameliorates liver injury in a murine aGvHD model by decreasing inflammatory responses via upregulation of HO-1. 38
30904623 2019
47
Endowing human CD8 T cells with a veto-like recognition capacity via the electroporation of MHC-I/CD3ζ mRNA. 38
30904624 2019
48
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. 38
31433496 2019
49
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. 38
30518980 2019
50
High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia. 38
31034759 2019

Variations for Hematopoietic Stem Cell Transplantation

Expression for Hematopoietic Stem Cell Transplantation

Search GEO for disease gene expression data for Hematopoietic Stem Cell Transplantation.

Pathways for Hematopoietic Stem Cell Transplantation

Pathways related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TNF KIR3DL1 KIR2DL3 KIR2DL1 IL6 IL2
2
Show member pathways
13.45 KIR3DL1 KIR2DL3 KIR2DL1 HLA-E HLA-C HLA-B
3
Show member pathways
13.32 TNF IL6 IL2 IL10 IFNG HLA-E
4
Show member pathways
13.05 TNF IL6 IL2 IL10 IFNG
5
Show member pathways
13 TNF IL6 IL2 HLA-E HLA-C HLA-B
6
Show member pathways
12.97 TNF IL6 HLA-E HLA-C HLA-B HLA-A
7
Show member pathways
12.62 TNF IL6 IL2 IL10 IFNG
8
Show member pathways
12.61 TNF IL6 IL2 IL10 IFNG
9 12.59 TNF IL2 IL10 IFNG CTLA4
10
Show member pathways
12.56 IFNG HLA-E HLA-C HLA-B HLA-A
11
Show member pathways
12.54 TNF IL6 IL2 IL10 IFNG CTLA4
12
Show member pathways
12.46 HLA-E HLA-C HLA-B HLA-A
13 12.39 HLA-E HLA-C HLA-B HLA-A
14
Show member pathways
12.38 IL6 IL2 IL10 IFNG
15
Show member pathways
12.37 TNF MTHFR IL6 IL2 IFNG
16 12.32 TNF IL6 IL2 HLA-E HLA-C HLA-B
17 12.31 HLA-E HLA-C HLA-B HLA-A
18 12.27 TNF IL6 IL10 IFNG CLEC7A
19
Show member pathways
12.23 TNF IL6 IL2 IL10 CLEC7A
20
Show member pathways
12.18 TNF KIR3DL1 KIR2DL3 KIR2DL1 IL6 IL2
21 12.17 HLA-E HLA-C HLA-B HLA-A CLEC7A
22 12.13 HLA-E HLA-C HLA-B HLA-A CTLA4
23
Show member pathways
12.13 TNF KIR3DL1 KIR2DL3 KIR2DL1 IL2 IFNG
24 12.07 KIR2DL3 KIR2DL1 IL6 HLA-E HLA-C HLA-B
25
Show member pathways
12.06 TNF IL6 IL2 IL10 IFNG
26
Show member pathways
12.04 IL6 IL2 IL10 IFNG
27 12.03 TNF IL6 IL2 IFNG
28
Show member pathways
12.02 TNF IL6 IL2 IL10 IFNG HLA-E
29
Show member pathways
12 TNF IL6 IFNG
30 12 TNF IL6 IL2 IL10 IFNG
31 11.96 TNF IL6 IL10 IFNG
32 11.95 TNF IL6 IL10
33
Show member pathways
11.94 IL2 IFNG HLA-A
34 11.93 KIR3DL1 KIR2DL3 KIR2DL1 HLA-E HLA-C HLA-B
35 11.91 TNF IL6 IFNG CTLA4
36 11.9 IL6 IL2 IL10 IFNG
37 11.84 TNF IL2 IL10 IFNG
38
Show member pathways
11.81 TNF IL2 IFNG CTLA4
39 11.8 IL6 IL2 IFNG
40 11.76 TNF IL6 IL10
41 11.74 TNF IL6 IL2 IL10 IFNG
42
Show member pathways
11.71 TNF IL6 IL2 IFNG
43 11.71 TNF IL6 IL2 IL10 IFNG
44
Show member pathways
11.69 TNF IL2 IFNG HLA-A
45 11.59 TNF IL6 IL2 IFNG
46 11.57 TNF IL6 IL10 IFNG
47 11.56 TNF IL6 IL10
48 11.55 TNF IL2 IFNG
49 11.53 IL2 IL10 IFNG
50 11.52 TNF IL6 IFNG

GO Terms for Hematopoietic Stem Cell Transplantation

Cellular components related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 TNF KIR3DL1 KIR2DL3 KIR2DL1 HLA-B HLA-A
2 cell surface GO:0009986 9.85 TNF HLA-E HLA-C HLA-B HLA-A
3 early endosome membrane GO:0031901 9.67 HLA-E HLA-C HLA-B HLA-A
4 recycling endosome membrane GO:0055038 9.62 HLA-E HLA-C HLA-B HLA-A
5 phagocytic vesicle membrane GO:0030670 9.56 HLA-E HLA-C HLA-B HLA-A
6 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-E HLA-C HLA-B HLA-A
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-E HLA-C HLA-B HLA-A
8 MHC class I protein complex GO:0042612 8.92 HLA-E HLA-C HLA-B HLA-A
9 plasma membrane GO:0005886 10.17 TNF KIR3DL1 KIR2DL3 KIR2DL1 HLA-E HLA-C

Biological processes related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.93 IL2 IFNG HLA-E CTLA4
2 cytokine-mediated signaling pathway GO:0019221 9.92 TNF IL6 IL2 IL10
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.82 TNF IL6 IL10
4 defense response to Gram-positive bacterium GO:0050830 9.81 TNF IL6 HLA-E
5 type I interferon signaling pathway GO:0060337 9.81 HLA-E HLA-C HLA-B HLA-A
6 regulation of immune response GO:0050776 9.8 KIR3DL1 KIR2DL3 KIR2DL1 HLA-E HLA-C HLA-B
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 IL6 IL2 IFNG
8 antigen processing and presentation GO:0019882 9.78 HLA-E HLA-C HLA-B HLA-A
9 response to glucocorticoid GO:0051384 9.77 TNF IL6 IL10
10 humoral immune response GO:0006959 9.77 TNF IL6 IFNG
11 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.73 HLA-E HLA-C HLA-B HLA-A
12 interferon-gamma-mediated signaling pathway GO:0060333 9.72 IFNG HLA-E HLA-C HLA-B HLA-A
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.71 HLA-E HLA-C HLA-B HLA-A
14 regulation of regulatory T cell differentiation GO:0045589 9.7 IL2 IFNG CTLA4
15 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL2 HLA-E
16 positive regulation of T cell mediated cytotoxicity GO:0001916 9.67 HLA-E HLA-C HLA-B HLA-A
17 positive regulation of glial cell proliferation GO:0060252 9.66 TNF IL6
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 TNF IFNG
19 negative regulation of B cell proliferation GO:0030889 9.65 IL10 CTLA4
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 TNF IL10
21 negative regulation of growth of symbiont in host GO:0044130 9.64 TNF IL10
22 protection from natural killer cell mediated cytotoxicity GO:0042270 9.63 HLA-E HLA-B HLA-A
23 negative regulation of lipid storage GO:0010888 9.62 TNF IL6
24 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
25 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 TNF IL10
27 receptor biosynthetic process GO:0032800 9.57 TNF IL10
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IFNG
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 TNF IFNG
30 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.46 HLA-E HLA-C HLA-B HLA-A
31 immune response GO:0006955 9.44 TNF KIR3DL1 KIR2DL3 KIR2DL1 IL6 IL2
32 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.26 HLA-E HLA-C HLA-B HLA-A
33 immune system process GO:0002376 10.02 IL2 HLA-C HLA-B HLA-A CTLA4 CLEC7A

Molecular functions related to Hematopoietic Stem Cell Transplantation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 TNF IL6 IL2 IL10 IFNG
2 beta-2-microglobulin binding GO:0030881 9.26 HLA-E HLA-A
3 peptide antigen binding GO:0042605 8.92 HLA-E HLA-C HLA-B HLA-A
4 protein binding GO:0005515 10.03 TNF KIR3DL1 KIR2DL3 KIR2DL1 IL6 IL2

Sources for Hematopoietic Stem Cell Transplantation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....